Business ❯ Healthcare

Biopharmaceuticals

Drug Development Oncology Clinical Trials Manufacturing Product Development Company Operations Dermatology Research and Development Contract Research Organizations Cardiovascular Medicine

Simulations Plus Tops Quarter, Cuts 2026 EPS Outlook as Shares Slip

Regulatory moves favoring non‑animal testing signal steady demand for the company’s drug‑modeling tools.

ADMA Biologics Denies Short-Seller Report as Shares Rebound and Law Firms Launch Probes

Biofrontera Reports Record 2025 Revenue of $41.7 Million and Best-Ever Q4 at $17.1 Million

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

Cantor Raises Innoviva Target to $32 After Q4 Beat on China XacDuro Builds

Almirall Tops €1.1 Billion in 2025 Sales as Profit Quadruples, Issues 2026 Guidance

AstraZeneca Shifts U.S. Listing to NYSE as Nasdaq ADSs End Jan. 30

Biocon Closes Rs 4,150 Crore QIP to Buy Out Viatris Stake in Biocon Biologics

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Biocon Moves to Fully Merge Biocon Biologics in $5.5 Billion Deal, Buys Out Viatris Stake

MPM BioImpact Exits MBX, MoonLake, Crinetics in Q3, SEC Filing Shows

Day One to Acquire Mersana in Backloaded Deal Worth Up to $285 Million

CorMedix Shares Jump After Q3 Beat as Company Lifts 2025 Outlook

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Analyst Warns Eli Lilly’s GLP-1 Lead Is Fading as CFRA Lifts Rating to Buy

Liquidia Reports 900+ Yutrepia Prescriptions in 11 Weeks, Targets Profitability Within 3–4 Quarters

Biocon Launches ₹4,500 Crore QIP at ₹340.20 Floor Price